Status
Conditions
Treatments
About
This study is examining the effects of six weeks of inspiratory muscle strength training (IMST) on outcomes related to pulmonary hypertension. This study leverages previous cardiopulmonary exercise test (CPET) results and a pre-existing upcoming CPET to examine the effects of IMST on cardiopulmonary pressures and exercise tolerance and ability.
Full description
PH is a condition characterized by abnormally high blood pressure in the lungs (i.e., pulmonary arterial pressure), which impacts heart function and reduces exercise tolerance. This study will assess whether six weeks of a breathing exercise called IMST can improve heart and lung function as well as exercise capacity for individuals with PH.
For this study, patients will be asked to perform IMST for the six weeks prior to their next scheduled clinical standard of care assessment of their PH. The goal of this study is to determine whether IMST reduces pulmonary arterial pressure and improves exercise tolerance in individuals with PH. This study will be minimally invasive, as it simply adds a safe, well-tolerated, non-invasive respiratory training to the participants' standard of care and leverages their existing PH assessment data to evaluate the impact of IMST on PH.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Current smoker or have smoked in the last 10 years
Unable or unwilling to undergo routine functional testing of their PH (i.e., 6-minute walk distance).
Presence of significant cardiovascular or respiratory conditions other than PH, including but not limited to:
History of a major cardiovascular event, such as a myocardial infarction or stroke, within the last 6 months
Individuals with an implanted pacemaker or other significant cardiac devices
History of neurological, respiratory, head and neck, or thoracic surgeries, or conditions such as a collapsed lung or perforated eardrum
Pregnant individuals or those actively trying to become pregnant
Individuals with any of the following: chronic laryngitis, chronic bronchitis, emphysema, pneumonia, tuberculosis, chronic cough, extremely high blood pressure (>170/100), neurological problems, scoliosis, organ transplants, HIV or other immunocompromising conditions, or autoimmune disease.
Primary purpose
Allocation
Interventional model
Masking
4 participants in 1 patient group
Loading...
Central trial contact
Josie Mazzone, MS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal